Rodorubicin (Cytorhodin S) is a tetraglycosidic anthracycline with preclinical antitumor activity[1].
References
[1] Verweij J, et, al. Phase I studies of rodorubicin single bolus and daily times five, once every three weeks in patients with advanced solid tumors. Eur J Cancer Clin Oncol. 1989 Apr;25(4):627-32. DOI:10.1016/0277-5379(89)90196-x
